Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that the New England Journal of Medicine will publish findings from a respiratory syncytial virus (RSV) challenge study for ALS-008176, a cytidine nucleoside analog with activity against RSV.

Originally posted here:
New data shows ALS-008176 drug safe and effective against RSV infection

Scroll to Top